It is widely accepted that hypertension constitutes a significant cardiovascular risk factor and that treating high blood pressure (BP) effectively reduces cardiovascular risk.
| BACKG ROU N D
Elevated blood pressure (BP) has been irrefutably shown to be associated with cardiovascular mortality and morbidity. Furthermore, there is definitive evidence to show that treatment of elevated BP is highly effective. The big challenge now is to identify and define the BP threshold at which clinically relevant hypertension should be diagnosed and BP targets during treatment.
For the past quarter of a century, the diagnosis of hypertension in adults has been based on systolic BP (SBP) ≥140 mm Hg and/ or diastolic BP (DBP) ≥90 mm Hg. These thresholds were chosen arbitrarily and have been in use since 1993 when the new classification of hypertension was introduced by the Fifth Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure (JNC5). 1 This report changed the way hypertension was diagnosed, moving from a diagnosis based on DBP in earlier JNC reports, to one based on both SBP and DBP. 1, 2 The JNC committee was recently replaced by a team of several medical societies led by the American College of Cardiology (ACC) and the American Heart Association (AHA). In November 2017, these organizations introduced another change in the threshold for diagnosing hypertension and the treatment target, reducing it by 10 mm Hg to a BP of ≥130/80 mm Hg. 3 This new lower BP threshold has caused a lot of ongoing debate, not only in the United States but also throughout the world. 4-6
| RECOMMENDED D IAG NOS TI C B P THRE S HOLD AND TARG E T B P IN A S IA
After the publication of the ACC/AHA guidelines, many countries reviewed and updated their own national guidelines. The European guidelines, 7 released in August 2018, retained a diagnostic BP threshold of ≥140/90 mm Hg, as did almost all countries/regions in Asia. Thus, although BP thresholds for the diagnosis of hypertension are relatively consistent across Asia (Table 1) , some countries/regions recommend a lower threshold for defining BP control (<130/80 mm Hg), consistent with the European and US guidelines. 3, 7 In contrast to the US guidelines, which recommend the same BP target for all patients with hypertension, regardless of comorbidities, many Asian countries/regions recommend different target BP depending on the comorbidity and risk profile. In addition, there is variation between countries/regions in the target recommendations for patients with the same comorbidity (Table 1 ).
| B P CONTROL S TATUS IN A S IA
An important issue in Asia is not just the high prevalence of hypertension, particularly in some countries/regions, but also the low level of awareness and treatment rates in many regions, as previously reported ( Table 2) . 8 A study done by the HOPE Asia Network was the first to investigate current home BP control status in eleven different Asian countries/regions using standardized home BP measurements taken with the same validated home BP monitoring device with data memory. 9 The results showed that BP control based on office BP of <140/90 mm Hg and a home BP of <135/85 mm Hg can be achieved by a relatively high proportion of specialist centers in Asia. 10 However, there was extremely wide variation between control rates achieved in different regions, from 70% in Taiwan to only 5.5% in Pakistan. Furthermore, the effect of lowering diagnostic and therapeutic thresholds to levels recommended in the 2017 ACC/AHA guidelines differed by country/region (Tables 3 and 4 ). 
| IMPLIC ATIONS
Adopting a lower BP threshold will mean a higher prevalence of hypertension and even worse control rates of hypertension in much of Asia. While the debate on the threshold and treatment target is still ongoing, several Asia-specific hypertension features have to be considered. Some of these features can be summarized as follows. Stroke is a more common complication of hypertension than coronary artery disease in many Asian countries/regions. 11 The association between higher SBP and cardiovascular events is steeper in Asians vs Westerners. 12 Asians are likely to develop high BP even
in the presence of mild obesity. 13 Many countries/regions in Asia have a high population intake of salt and show increased salt sensitivity. 14, 15 There are also common hypertension phenotypes in Asia, characterized by morning BP surge, nocturnal hypertension and greater BP variability. [16] [17] [18] [19] [20] [21] Based on all these differences between Asians and Caucasians, is there any merit in recommending and adopting the lower BP threshold for diagnosis and treatment target in Asia? Although the cardiovascular risk profile of Asian patients with hypertension means that it makes theoretical sense to lower diagnostic and therapeutic BP thresholds, there are currently no data from robust randomized clinical trials for the benefits of the lower targets in preventing cardiovascular disease (CVD) and reducing cardiovascular risk, particularly in high-risk patients and especially not in Asian populations. 5 This was the rationale cited by a number of Asian countries for leaving current guidelines unchanged for the time being. There is also concern about lowering the clinic BP treat- Overall, Asian experts from the HOPE Asia Network refer to the step-by-step approach to BP lowering and targets recommended by an Asian consensus 23 as the current best approach in the region. The three-step approach is to lower morning home SBP to 145 mm Hg (first step) then to 130 mm Hg (second step) and to 125 mm Hg (third step). This is consistent with Asian data from the Japan Morning Surge-Home Blood Pressure (J-HOP) and Home blood pressure measurement with Olmesartan Naive patients to Establish Standard Target blood pressure (HONEST) studies indicating that morning home BP should be controlled to at least <145 mm Hg to reduce the risk of cardiovascular events [24] [25] [26] [27] and that achieving a SBP <125 mm Hg should reduce the CVD event rate even further.
| CON CLUS IONS
Hypertension awareness and control is poor in most Asian countries/regions, even when defined using the higher BP threshold of ≥140/90 mm Hg. While treating BP at lower levels and getting to lower targets may be beneficial to many Asians patients, who are at higher cardiovascular risk compared with Caucasians, there is still 
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